PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (the “Company”) (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announced today that it will hold a conference call on March 14, 2014 to discuss the financial results for the fourth quarter of 2013. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
The conference call is scheduled to begin at 11:00 a.m. (Eastern Time). The results will be released before the opening of the market that same day.
To access the conference call, U.S.-based listeners should dial 888-563-6275 and international listeners should dial 706-634-7417. All listeners should provide the following passcode: 9188900. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company’s website at www.dermasciences.com.
Following the conclusion of the conference call, a replay will be available through March 20, 2014 and can be accessed by dialing (855) 859-2056 from within the U.S. or (404) 537-3406 from outside the U.S. All listeners should provide passcode 9188900. The webcast will be available for 30 days.
About Derma Sciences, Inc.
Derma Sciences is a tissue regeneration company focused on advanced wound and burn care. It offers a line of products with patented technologies to help better manage chronic and hard-to-heal wounds, many of which result from diabetes and poor vascular functioning. During the third quarter of 2014 Derma Sciences expects to begin marketing AMNIOEXCEL® and AMNIOMATRIX®, two novel human placental-derived tissue products for wound healing. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for barrier protection against microbes and other contaminants. Its pharmaceutical wound care products include DSC127, which is currently in Phase 3 clinical trials for the healing of diabetic foot ulcers. The drug is also part of a BARDA grant program for the healing/prevention of tissue damage due to ionizing radiation exposure. The patented API peptide used in DSC127 is also in pre-clinical testing for scar prevention/reduction. The Company also offers a full product line of traditional dressings.
For more information please visit www.dermasciences.com.